Known targets — ChEMBL curated mechanism
ADRA2AADRA2BADRA2CADRB2AGTR1AVPR1AAVPR1BAVPR2BDKRB2CALCRCHRNA3CHRNB4ESR1ESR2GHSRGNRHRGSC1HSPA8MALT1MC1RMC4RNOS1NOS2NOS3OPRK1OXTRRAMP1RAMP2RAMP3SCN5ASSTR1SSTR2SSTR3SSTR4SSTR5dacAdacBdacCfolPftsImrcAmrcBmrdArplArplBrplCrplDrplErplFrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmFrpmGrpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Nonane. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ESR1 known ✓ | P03372 | 1/20 | 0.63 |
| ▸ | GPR84 | Q9NQS5 | 7/20 | 0.63 |
| ▸ | PPARG | P37231 | 7/20 | 0.63 |
| ▸ | PPARD | Q03181 | 7/20 | 0.63 |
| ▸ | PPARA | Q07869 | 7/20 | 0.63 |
| ▸ | HDAC11 | Q96DB2 | 5/20 | 0.63 |
| ▸ | TSHR | P16473 | 5/20 | 0.63 |
| ▸ | PTPN1 | P18031 | 3/20 | 0.63 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.63 |
| ▸ | TLR2 | O60603 | 2/20 | 0.63 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.63 |
| ▸ | FABP4 | P15090 | 2/20 | 0.63 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.63 |
| ▸ | SLC22A6 | Q4U2R8 | 1/20 | 0.63 |
| ▸ | SLC22A8 | Q8TCC7 | 1/20 | 0.63 |
| ▸ | MEN1 | O00255 | 1/20 | 0.63 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.63 |
| ▸ | PDE4A | P27815 | 1/20 | 0.63 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.63 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.63 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Dodecane SCHEMBL28390898 | 1.00 | GPR84 (0.63) | GPR84PPARGPPARDPPARAHDAC11 | |
| Octane SCHEMBL6663108 | 1.00 | GPR84 (0.63) | GPR84PPARGPPARDPPARAHDAC11 | |
| Heptane SCHEMBL16058605 | 1.00 | GPR84 (0.63) | GPR84PPARGPPARDPPARAHDAC11 | |
| Hexadecane SCHEMBL14718769 | 1.00 | GPR84 (0.63) | GPR84PPARGPPARDPPARAHDAC11 | |
| Dodecane SCHEMBL14718935 | 1.00 | GPR84 (0.63) | GPR84PPARGPPARDPPARAHDAC11 | |
| Nonane SCHEMBL23929397 | 1.00 | GPR84 (0.63) | GPR84PPARGPPARDPPARAHDAC11 | |
| Decane SCHEMBL14718768 | 1.00 | GPR84 (0.63) | GPR84PPARGPPARDPPARAHDAC11 | |
| Undecane SCHEMBL14719515 | 1.00 | GPR84 (0.63) | GPR84PPARGPPARDPPARAHDAC11 | |
| Heptane SCHEMBL1049410 | 1.00 | GPR84 (0.63) | GPR84PPARGPPARDPPARAHDAC11 | |
| Heptane SCHEMBL28166995 | 1.00 | GPR84 (0.63) | GPR84PPARGPPARDPPARAHDAC11 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-112034681-B | Composition for forming organic film, pattern forming method, and polymer | 信越化学工业株式会社 | 2024-08-20 | — | — | CN | disclosed |
| CN-101448785-B | Novel dipeptidyl peptidase iv inhibitors and processes for preparation and pharmaceutical compositions thereof containing the same | MATRIX LAB LTD | 2013-03-27 | — | — | CN | disclosed |
| EP-1569694-B1 | POLYAMINE CONJUGATES WITH ACIDIC RETINOIDS AND PREPARATION THEREOF | PAPAIOANNOU DIONYSIOS (GR) | 2009-11-25 | — | — | EP | disclosed |
| CN-101448785-A | Novel dipeptidyl peptidase IV inhibitors and processes for their preparation and pharmaceutical compositions containing them | MATRIX LAB LTD (IN) | 2009-06-03 | — | — | CN | disclosed |
| US-7517913-B2 | Polyamine conjugates with acidic retinoids and preparation thereof | PAPAIOANNOU DIONYSIOS | 2009-04-14 | — | — | US | disclosed |
| CN-101346387-A | Pyrimido- [4, 5-]-oxazines for use as DGAT inhibitors | ASTRAZENECA AB (SE) | 2009-01-14 | — | — | CN | disclosed |
| US-7402602-B2 | Imidazole derivatives modulating the sodium channels | SOCIETE DE CONSEILS DE RECHERCHES ET D'APPLICATIONS SCIENTIFIQUES (S.C.R.A.S) (FR) | 2008-07-22 | — | — | US | disclosed |
| US-20070099975-A1 | Imidazole derivatives modulating the sodium channels | SOCIETE DE CONSEILS DE RECHERCHES ET D'APPLICATIONS SCIENTIFIQUES (S.C.R.A.S.) | 2007-05-03 | — | — | US | disclosed |
| US-7157483-B2 | Imidazole derivatives modulating the sodium channels | SOCIETE DE CONSEILS DE RECHERCHES ET D'APPLICATIONS SCIENTIFIQUES (S.C.R.A.S.) (FR) | 2007-01-02 | — | — | US | disclosed |
| US-20060189696-A1 | Polyamine conjugates with acidic retinoids and preparation thereof | PAPAIOANNOU DIONYSIOS | 2006-08-24 | — | — | US | disclosed |
| US-20060069146-A1 | Imidazole derivatives modulating the sodium channels | SCRAS | 2006-03-30 | — | — | US | disclosed |
| EP-1569694-A1 | POLYAMINE CONJUGATES WITH ACIDIC RETINOIDS AND PREPARATION THEREOF | Papaioannou, Dionysios (GR) | 2005-09-07 | — | — | EP | disclosed |
| US-20050027143-A1 | Process for the preparation of beta-ionylideneacetaldehyde | RANBAXY LABORATORIES LIMITED (IN) | 2005-02-03 | — | — | US | disclosed |
| US-20040198792-A1 | Imidazole derivatives modulating the sodium channels | IPSEN PHARMA S.A.S. (FR) | 2004-10-07 | — | — | US | disclosed |
| EP-1421054-A2 | PROCESS FOR THE PREPARATION OF BETA-IONYLIDENEACETALDEHYDE | RANBAXY LABORATORIES, LTD. (IN) | 2004-05-26 | — | — | EP | disclosed |
| WO-2004018001-A1 | POLYAMINE CONJUGATES WITH ACIDIC RETINOIDS AND PREPARATION THEREOF | PAPAIOANNOU DIONYSIOS (GR) | 2004-03-04 | — | — | WO | disclosed |
| WO-2003018522-A2 | PROCESS FOR THE PREPARATION OF BETA-IONYLIDENEACETALDEHYDE | RANBAXY LABORATORIES LIMITED (IN) | 2003-03-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060189696-A1 | Polyamine conjugates with acidic retinoids and preparation thereof | RNASEL, RNASEH1, SNRPE | ESR1 4166/4885GPR84 2314/4885PPARG 1017/4885 |
| US-20040198792-A1 | Imidazole derivatives modulating the sodium channels | SCN1A, SCN1B, TRPV1 | ESR1 3711/4885GPR84 1535/4885PPARG 2066/4885 |
| US-20070099975-A1 | Imidazole derivatives modulating the sodium channels | SCN2B, KCNJ2, SCN1B | ESR1 3764/4885GPR84 1788/4885PPARG 2151/4885 |
| US-20050027143-A1 | Process for the preparation of beta-ionylideneacetaldehyde | ALDH1A2, ADH1B, ADH4 | ESR1 4362/4885GPR84 1976/4885PPARG 1363/4885 |
| US-20060069146-A1 | Imidazole derivatives modulating the sodium channels | SCN1B, SCN1A, SCN2B | ESR1 4140/4885GPR84 2060/4885PPARG 2336/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.